{"schema_version":"secwatch.filing_event.v1","accession":"0001664710-23-000064","form_type":"8-K","ticker":"KROS","cik":"0001664710","company_name":"Keros Therapeutics, Inc.","filed_at":"2023-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.990559+00:00","generated_at":"2026-06-08T21:05:21.365314+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Keros Therapeutics reports Q3 2023 net loss of $39.4M; advances KER-050, deprioritizes KER-047","bullets":["Net loss of $39.4M in Q3 2023 vs $23.5M in Q3 2022, driven by increased R&D spending.","R&D expenses rose to $34.1M from $21.0M; G&A rose to $9.1M from $6.9M.","Cash and equivalents of $287.9M provide runway into Q4 2025.","KER-047 program deprioritized; Phase 2 trial in MDS/myelofibrosis being terminated early.","KER-065 Phase 1 trial in healthy adults expected to start in Q1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001664710-23-000064","json":"https://secwatch.observer/filing/0001664710-23-000064.json","markdown":"https://secwatch.observer/filing/0001664710-23-000064.md","text":"https://secwatch.observer/filing/0001664710-23-000064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1664710/000166471023000064/0001664710-23-000064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1664710/000166471023000064/kros-20231106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T21:05:21.365314+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e9b3e3b1dc47c975bd1937e1c9a984ca6cfe85b2","claim":"Keros Therapeutics, Inc. reported for the quarter ended September 30, 2023 results: net income net loss of $39.4 million.","evidence_excerpt":"Keros reported a net loss of $39.4 million in the third quarter of 2023 as compared to a net loss of $23.5 million in the third quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1664710/000166471023000064/0001664710-23-000064-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the quarter ended September 30, 2023"},{"label":"Net income","value":"net loss of $39.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}